Navigation Links
Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
Date:10/13/2010

LEXINGTON, Ky., Oct. 13 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), the worldwide leader in genetically modified rats, has announced today that it has entered into an exclusive marketing and distribution agreement with Charles River Laboratories, a leading global provider of research models and services.

The license includes two of Transposagen's high-value TGEM™ Knockout Rat Models, one rat line contains a mutation in the p53 gene, the most studied tumor suppressor, and one rat line contains a mutation in the Bcrp gene, encoding an important drug transporter. The p53 gene is the gene most commonly mutated in many human cancers. The p53 TGEM™ Knockout Rat Model recapitulates human cancers and is the only fully phenotyped p53 knockout rat model, now available with complete tumor spectrum and survival data.  

"Our p53 and Bcrp TGEM™  Knockout Rat Models, developed with our academic collaborators at the Hubrecht Institute in the Netherlands, are the first of their kind in the world," said Dr. Eric Ostertag, the President and CEO of Transposagen. "For the p53 TGEM™ Knockout Rat Model in particular, we have years of phenotyping data showing that this research model faithfully produces a wide variety of tumors. Add this to the outstanding breeding standards and quality control offered by our partner, Charles River Laboratories, and customers can be certain that they are getting a quality research model."

These two unique TGEM™ Knockout Rat Models will enhance Charles River's ability to provide its global clients with unique solutions in the drug development process from target validation to toxicology and carcinogenicity testing. Dr. Iva Morse, Corporate Vice President, Global Research Model Services at Charles River, commented, "Charles River is extremely pleased to offer knockout rat models to our clients for the first time by partnering with Transposagen Biop
'/>"/>

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MKS Instruments Announces Third Quarter 2010 Earnings Conference Call
2. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
3. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
4. Boston Scientific Announces Global Launch of Journey™ Guidewire
5. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
6. CORRECTED - Akorn, Inc. Announces Date Change for Third Quarter 2010 Earnings Release and Conference Call
7. Prime Therapeutics Announces URAC Accreditation
8. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. Cellectis bioresearch Announces Establishment of Subsidiary in the US
10. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
11. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  PCI is pleased to announce it has ... leading provider of Clinical Trial Services and Temperature ... Wales in the United ... presence in the UK/EU to support global investigational ... and distribution capacity, as well as consultative services ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)... , September 18, 2014 ... http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition of ... Report"  report to their offering.  ... the worldwide markets for Sugar Alcohols in ... Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care Products, ...
Breaking Medicine Technology:PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3
(Date:9/19/2014)... 2014 Are you tired of having ... with seasonal allergies or sinus congestion? Fortunately, an inventor ... , She conceived of Nose Pal to avoid ... nose in public. Since it prevents nasal drip and ... conditions, particularly when cooking or working closely with others. ...
(Date:9/19/2014)... (HealthDay News) -- As kids transition from elementary to ... according to a recent study. But the ... found that verbal and physical bullying declines as students ... and prevention strategies must address all types of bullying ... girls, the researchers said. The study was published recently ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... According to a report from HarrisMartin ... Xarelto, named as defendants in several lawsuits filed in ... the court to dismiss those suits because the alleged ... with Philadelphia.* The cases include, for instance, Fontan v. ... Comm. Pls., Philadelphia Cty.), which was brought by a ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Your brain structure could help predict ... study suggests. Researchers at Yale University found those with ... the parietal cortex may be more likely to engage in ... , , The study, funded by the U.S. National Institute ... women living in the Northeast. The researchers sought to determine ...
Breaking Medicine News(10 mins):Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2
... Indiana University study found that young, female breast cancer ... and are interested in using sexual enhancement products to ... Cancer Survivors: Their sexual function and interest in sexual ... the journal Cancer Nursing . , The study ...
... reduced chances by 26% , , SUNDAY, Nov. 9 (HealthDay News) ... an extra benefit: a reduction in their risk of developing ... under the age of 52, according to research that was ... in New Orleans. , The findings, the first to demonstrate ...
... to protect healthy men, either , , SUNDAY, Nov. 9 ... doubt on the cardiac benefits of either low-dose aspirin ... low-dose aspirin did not reduce the risk of cardiovascular ... Harvard researchers concluded that neither vitamin E nor vitamin ...
... Low-dose aspirin as primary prevention did not appear to ... of coronary, cerebrovascular and peripheral vascular events in patients ... in JAMA . However, aspirin did significantly reduce ... The article is being released early online Sunday, November ...
... informed its readers of serious drug reactions and fatalities, which have ... as Heparin. The drug, from Baxter Healthcare, was found to be ... ... Denver (PRWEB) November 9, 2008 -- LegalView.com, the number one legal ...
... they have risk factors that could lead to coronary ... -- Despite certain risk factors, Hispanic patients were 57 ... bypass surgery (CABG) one year after successful angioplasty to ... It also found that Hispanics were less likely to ...
Cached Medicine News:Health News:Sexual intimacy and breast cancer survivors: New research 2Health News:Flu Shots Lower Risk of Blood Clots 2Health News:Flu Shots Lower Risk of Blood Clots 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 2Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 3Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 4Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 2Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 3Health News:LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin 4Health News:Hispanics Less Likely to Get Repeat Artery Surgery 2
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: